REGENEREX PHARMA, INC.
RGPXInvestment snapshot
Positive
1
BUY / PASS
Neutral / negative
0 / 1
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 2
Positive margin of safety
Key risk
No clean pass — all 2 investors flag at least one profitability criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Piotroski F-Score | Sleep Scale Economies Shared |
|---|---|---|
| Verdict | PASS | FAIL |
| Score | ||
| Analysis | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A |
| Margin of Safety | N/A | N/A |
| Financial Basis | Annual history · FY 2024 Latest source filing: 2025-06-30 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-06-30 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Profitability0% pass✓ 2✗ 3▾
No clean pass — all 2 investors flag at least one profitability criterion
Net Income / Total Assets-200.05%✗PiotroskiROA > 0ROA Change YoY-462.23% -> -200.05% (delta: +262.19%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-128.67%, ROA=-200.05%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY✗PiotroskiImproved YoYRevenue growth vs. gross and operating margin trend✗SleepRevenue rising; gross margin flat or falling; operating margin holding - Cash Flow0% pass✓ 1✗ 2▾
No clean pass — all 2 investors flag at least one cash flow criterion
Operating Cash Flow$-1.6M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-128.67%, ROA=-200.05%✓PiotroskiCFO/Assets > ROAPositive Operating Cash Flow frequency3/12 years positive✗SleepPositive OCF in >= 70% of available years - Efficiency0% pass✓ 1✗ 2▾
No clean pass — all 2 investors flag at least one efficiency criterion
Current Ratio Change YoY0.00 -> 0.13✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY✗PiotroskiImproved YoYROIC (5-year)✗SleepROIC > 12% in a majority of years - Verdicts50% pass✓ 1✗ 1▾
Split decision: 1 PASS · 1 FAIL
Overall verdict✓PiotroskiPASS (F-Score 4)✗SleepFAIL (0/6)
Business & financials
Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2025-09-30 2024-10-01 – 2025-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, net income, operating income, ebit, interest expense. | Q2 · 2025-09-30 2025-07-01 – 2025-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow. | Q1 · 2025-06-30 2025-04-01 – 2025-06-30 Sources | FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
| FY 2020Sources
|
|---|---|---|---|---|---|---|---|---|
| Market Cap | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue | -- | -- | -- | -- | -- | -- | -- | $1.8K |
| Operating Income | -$2.7M | -$786.7K↓204% | -$633.8K↓149% | -$1.8M↑47% | -$3.5M↓3504% | -$96.2K↑24% | -$126.3K↓191% | -$43.4K |
| Net Income | -$3.2M | -$814.0K↓54% | -$663.6K↓143% | -$2.5M↑29% | -$3.5M↓2481% | -$137.3K↑30% | -$195.6K↑45% | -$353.8K |
| EPS (Diluted) | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross Margin | — | — | — | — | — | — | — | -13798.1% |
| Operating Margin | — | — | — | — | — | — | — | -2445.7% |
| ROE | 68.2% | — | — | 60.8%↓30% | 87.2%↑613% | 12.2%↓38% | 19.8%↓53% | 42.4% |
| Total Debt | $2.8M | $2.8M↑1% | $2.8M↑10% | $2.8M↑9% | $2.6M↑721% | $314.7K↓8% | $340.5K↑52% | $224.2K |
| Shareholders' Equity | -$4.7M | -$4.7M↑1% | -$4.5M↓5% | -$4.2M↓2% | -$4.1M↓262% | -$1.1M↓14% | -$985.6K↓18% | -$835.0K |
| Current Ratio | 0.01 | 0.01↑2500% | 0.04↑7336% | 0.13↑17415% | 0.00↓48% | 0.00↓88% | 0.01↓8% | 0.01 |
| Debt / Equity | -0.61 | -0.61↓2% | -0.63↓4% | -0.68↓7% | -0.64↓127% | -0.28↑19% | -0.35↓29% | -0.27 |
| Operating Cash Flow | -$2.4M | -$519.4K↓310% | -$477.9K↓764% | -$1.6M↓255% | -$457.5K↓501% | -$76.2K↓9% | -$69.9K↓12% | -$62.7K |
| Free Cash Flow | -- | -- | -- | -- | -- | -- | -- | -- |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
RGPX vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |